Sitafloxacin
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | J01MA21 (WHO) |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | 127254-12-0 |
PubChem (CID) | 461399 |
ChemSpider | 405945 |
UNII | 3GJC60U4Q8 |
ChEMBL | CHEMBL108821 |
Chemical and physical data | |
Formula | C19H18ClF2N3O3 |
Molar mass | 409.81 |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic[1] that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.
See also
References
- ↑ Anderson, DL. (Jul 2008). "Sitafloxacin hydrate for bacterial infections.". Drugs Today (Barc). 44 (7): 489–501. doi:10.1358/dot.2008.44.7.1219561. PMID 18806900.
Further reading
- Keating GM (April 2011). "Sitafloxacin: in bacterial infections". Drugs. 71 (6): 731–44. doi:10.2165/11207380-000000000-00000. PMID 21504249.
External links
- (Japanese) Gracevit グレースビット (PDF) Daiichi Sankyo Co. January 2008.
This article is issued from Wikipedia - version of the 5/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.